Update on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward
|
|
- Beverly Williams
- 8 years ago
- Views:
Transcription
1 Update on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward 33 rd Annual Internal Medicine Update December 5, 2015 Ryan C. Hedgepeth, MD, MS Chief of Urological Services, OPG 1
2
3 Screening for prostate cancer Rectal exam More common in advanced disease PSA test PSA available for two decades Sensitive and specific but not perfect Detects cancer earlier than rectal exam or symptoms
4 4 SEER: PSA and Prostate Cancer Deaths
5
6 6 Screening impact takes a long time
7 Prostate Cancer Over-detection Of all screen-detected cancers, an estimated 10-56% would not have become apparent or caused symptoms in the patients lifetimes, and the lead time for diagnosis is estimated at 5-12 years.
8 Compared to observation, prostatectomy did not significantly improve overall or cancer specific survival over a 12-year period (PSA era) in localized low-risk prostate cancer
9 Controversy of PSA screening Benefit: Apparent reduction in prostate cancer mortality Risks: Over-diagnosis of low-risk cancers (2/3 men) Treatment-related morbidity and mortality (9/10 men elect early definitive treatment) D USPSTF recommendations on PSA screening: Cooperberg MR et al. J Clin Oncol. 2010; 28: Welch HG at al. J NCI 2009; 101: Thompson IM et al. JAMA 2010; 304::
10 Current PSA Screening Guidelines ACS Start At 40/45/50 AUA 40/55 69 NCCN Start at 40 Fractionated after by PSA USPSTF None 10
11 11 Current PSA Screening Guidelines
12 Recent decline in prostate cancer incidence in the US, by age, stage, and Gleason score Cancer Medicine 2 DEC 2015 DOI: /cam4.549
13 Did USPSTF lead to changes in biopsy rates or cancer detection? University of Toronto - proponents of surveillance Referrals and prostate biopsy from 2008 to ,408 biopsies performed 1,601 (47.0%) Prostate cancers detected Low risk = 563 (16.5%) Intermediate / High risk = 914 (27%) Monthly Median # of: Biopsies Decreased 58 to 36 (p=0.003) Patients for 1 st biopsy Decreased 43 to 24 (p=0.03) Low risk Decreased 9 to 6 (p=0.012) Intermediate / High Risk!!! Decreased 18 to 10 (p<0.001) Bhindi, B. et al. J Urol May;193(5):
14 Did the USPSTF Recommendation lead to smarter screening practices? National Health Interview Survey: PSA-based screening from 2010 to 2013 Age 40 to 49: No change (13% to 11% p = 0.4) 50 to 59: Declined (33% to 25% p <.01) 60 to 74 Declined (51% to 44% p <.01) 75 & older Declined (44% to 37% p =.03) Did this help prevent unnecessary screening in men at high risk of dying in next 10 years? A large percentage of men were screened despite high risk of 9-year mortality approximately 1/3 older than 75 Approximately 1.4 million men age 65 years or older with a high risk (> 52%) of 9-year mortality were screened in
15 Patient Approach to USPSTF Recs Does exposure to USPSTF recommendation and controversy on treatment of prostate cancer: 1. Predict treatment decisional conflict? 2. Affect treatment choice? 3. Increase regret about PSA testing? Accurate knowledge uncommon (19%) Attitudes toward the recommendation were negative Majority (87%) remained highly supportive of annual PSA testing in men 50. Orom, H. Psychooncology Sep;24(9):
16 Patient Approach to USPSTF Recs Does exposure to USPSTF recommendation and controversy on treatment of prostate cancer: 1. Predict treatment decisional conflict? 2. Affect treatment choice? No No 3. Increase regret about PSA testing? No Orom, H. Psychooncology Sep;24(9):
17 Does PSA Screening Reduce Prostate Cancer Mortality? PLCO: No ERSPC: Yes The difference in the relative risk for mortality has stabilized in favor of screening; 0.85 at 9 years, 0.78 at 11 years, and 0.79 at 13 years
18 Does PSA testing reduce mortality? Over 14 years PSA test Increased the # of cancers detected by 50% BUT Reduced the risk of dying of prostate cancer by 44% in all men and 56% in screened men. The number needed to screen to prevent one death was
19 Treatment Regret in Prostate Cancer Associated with: Androgen-deprivation therapy Urinary bother Satisfaction with understanding potential treatment side effects Effect on the spousal relationship 19
20 Criticism of USPSTF Recommendation European randomized trial now shows significant survival advantage from 9 years on Inappropriate inclusion of very different trials in meta-analysis Lack of appreciation for the strong relationship between PSA and prostate cancer mortality Inadequate consideration of time-to-event (long delay between elevated PSA and death from prostate cancer) Overall mortality is not an appropriate endpoint Mortality risk of surgery exaggerated (0.5%) Vickers AJ, Lilja H. Time for another rethink on prostate cancer screening. Nat Rev Clin Oncol. 2011; 9:7-8.
21 Does the USPSTF Recommendation Do What it Intended to Do? Reduces incidence of prostate cancer? Across full spectrum of disease Temporary Does not change inappropriate screening Does not address overtreatment Reduces referrals and biopsies Decreased detection of Low, Intermediate, and High Risk Prostate cancers Downstream impact on mortality predicted to rise 21
22 If not then what doe the USPSTF Recommendation do? Identifies shortcomings in prostate cancer: Detection Practice patterns Treatment Led to increased awareness of Spectrum of disease Importance screening guidelines Need for better prognostic measures 22
23 What happens when popular option suddenly is not popular? 23
24 Newer PSA screening Tests 4KScore Blood test Patient specific probability of intermediate/high risk Measures total PSA, free PSA, intact PSA & hk2 Algorithm provides % probability of aggressive cancer Progensa PCA3 Urine test Detects overexpression of gene PCA3 Specific to prostate cancer Used to identify need for second biopsy Studies to look at use as screening tool 24
25 The real problem Finding more prostate cancer Finding aggressive prostate cancer
26 What type of prostate cancer?
27 Current process: Ultrasound Guided Prostate Biopsy
28 So what s the problem in detecting prostate cancer with ultrasound? Biopsy blind to the tumor(s) location Prostate cancer is the only solid-organ tumor diagnosed without image guidance in the hopes of accidentally hitting the tumor
29 Trans Rectal Ultrasound (TRUS) Wein et. al. Campbell-Walsh Urology. 9th ed. 2007:Philadephia, PA
30 Why not tumor directed biopsies? Standard of care for all other solid tumors such as breast, liver, etc. All requires imaging/seeing the tumor Problem with prostate cancer is ultrasound does not reliably identify tumors within the prostate
31 3T MRI of the prostate High resolution imaging of the prostate
32 Multiple ways to see tumors T2W DWI-ADC DCE-MRI MRS
33 Why fuse MRI and Ultrasound? MRI TRUS Temporal resolution Spatial resolution Sensitivity/Specificity Cost effective Temporal resolution Spatial resolution Sensitivity/Specificity Cost effective
34 MRI Ultrasound Fusion Biopsy UroNav EM Field Generator TRUS Probe Ultrasound UroNav Workspot UroNav EM Sensor
35 Fusion Biopsy setup
36 In real time
37 Advantages of Fusion Prostate Biopsy Office-based procedure Minimal additional patient discomfort for significant additional diagnostic yield Physicians do what they are best at: Diagnostic radiologist interprets prostate MRI Urologist performs prostate biopsy
38 1,003 patients Targeted fusion biopsy diagnosed: 30% more high-risk cancers 17% fewer low-risk cancers JAMA Jan 27;313(4):390-7
39 Predicting Prostate Cancer Risk Statistical Review of Clinicopathologic Parameters Nomograms Neural Networks Better performance in pre and postoperative prognostic prediction than the opinions of expert clinicians because based on patient volumes Fall short predicting at the individual level who ultimately fail after initial treatment 39
40 Complicated fixes benefit groups but not necessarily individuals 40
41 Predicting Prostate Cancer Behavior with Gene Markers Prolaris: Measures tumor cell growth in + prostate biopsy 46-gene expression signature = cell cycle RNA Low expression associated with low risk progression High expression associated with high risk progression ConfirmMDX Used in negative prostate biopsy Genes associated with prostate cancer Helps predict who needs additional biopsies and who does not 41
42 42 How big is your patient s risk?
43 Can Prostate MRI & Fusion Biopsy help robotic surgery outcomes? Novakovic, K and Pinto, P. CANCER: Principles and Practice of Oncology, 8th ed.
44 Prostate cancer localization: Correlation of MRI, biopsy and pathology
45 Patient selection: Pre-op risk stratification and surgical planning PSA Gleason score Prostate cancer burden Assess stage and planning: Extracapsular extension Seminal vesicle invasion Raskolnikov D, George AK et al. The role of MR image-guided biopsy in stratifiying men at risk for ECE at RP. J Urol 2014; in press Raskolnikov D, George AK et al. MRI and image-guided biopsy to detect SVI by Pca. J Endourol; 28:1283-9
46 Prostate MRI & Fusion Biopsy Fusion biopsy is an innovation in prostate cancer diagnosis and decision making: Improves detection of aggressive cancers Allows for better risk assessment Prostate 3T MRI Likely improves our operative approach and outcomes for robotic prostate surgery
47 47 Update: Prostate Cancer Screening
48 Update: Prostate Cancer Screening There is a mortality benefit to PSA screening USPSTF Recommendation is flawed but has pushed the focus of the disease appropriately Innovations in screening algorithms and gene tests will continue to improve screening accuracy 48
49 Update: Prostate Cancer Detection Innovations in imaging allow us to see potential tumors more clearly MRI Ultrasound Fusion biopsy delivers targeted prostate biopsies with improved detection Gene testing may further stratify prostate cancer risk 49
50 Update: Prostate Cancer Treatment Robotic Prostatectomy continues to show improved outcomes over open prostatectomy Active Surveillance has become an acceptable treatment option for low risk prostate cancer Prostate MRI and Fusion biopsy increase our ability to accurately categorize tumors for those who choose active surveillance HIFU approved in limited situations 50
51 Seeing in new ways
52 Thank You
The 4Kscore blood test for risk of aggressive prostate cancer
The 4Kscore blood test for risk of aggressive prostate cancer Prostate cancer tests When to use the 4Kscore Test? Screening Prior to 1 st biopsy Prior to negative previous biopsy Prognosis in Gleason 6
More informationPSA Screening and the USPSTF Understanding the Controversy
PSA Screening and the USPSTF Understanding the Controversy Peter C. Albertsen Division of Urology University of Connecticut Farmington, CT, USA USPSTF Final Report 1 Four Key Questions 1. Does PSA based
More information4/8/13. Pre-test Audience Response. Prostate Cancer 2012. Screening and Treatment of Prostate Cancer: The 2013 Perspective
Pre-test Audience Response Screening and Treatment of Prostate Cancer: The 2013 Perspective 1. I do not offer routine PSA screening, and the USPSTF D recommendation will not change my practice. 2. In light
More informationAdvances in Diagnostic and Molecular Testing in Prostate Cancer
Advances in Diagnostic and Molecular Testing in Prostate Cancer Ashley E. Ross MD PhD Assistant Professor Urology, Oncology, Pathology Johns Hopkins School of Medicine September 24, 2015 1 Disclosures
More informationPSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj.
PSA Testing 101 Stanley H. Weiss, MD Professor, UMDNJ-New Jersey Medical School Director & PI, Essex County Cancer Coalition weiss@umdnj.edu September 23, 2010 Screening: 3 tests for PCa A good screening
More informationTO SCREEN OR NOT TO SCREEN: THE PROSTATE CANCER
TO SCREEN OR NOT TO SCREEN: THE PROSTATE CANCER DILEMMA Thomas J Stormont MD January 2012 http://www.youtube.com/watch?v=8jd 7bAHVp0A&feature=related related INTRODUCTION A government health panel (the
More informationThe PLCO Trial Not a comparison of Screening vs no Screening
PSA Screening: Science, Politics and Uncertainty David F. Penson, MD, MPH Hamilton and Howd Chair of Urologic Oncology Professor and Chair, Department of Urologic Surgery Director, Center for Surgical
More informationProstate cancer. Christopher Eden. The Royal Surrey County Hospital, Guildford & The Hampshire Clinic, Old Basing.
Prostate cancer Christopher Eden The Royal Surrey County Hospital, Guildford & The Hampshire Clinic, Old Basing. Screening Screening men for PCa (prostate cancer) using PSA (Prostate Specific Antigen blood
More informationNewly Diagnosed Prostate Cancer: Understanding Your Risk
Newly Diagnosed Prostate Cancer: Understanding Your Risk When the urologist calls with the life-changing news that your prostate biopsy is positive for prostate cancer, an office appointment is made to
More informationRobert Bristow MD PhD FRCPC
Robert Bristow MD PhD FRCPC Clinician-Scientist and Professor, Radiation Oncology and Medical Biophysics, University of Toronto and Ontario Cancer Institute/ (UHN) Head, PMH-CFCRI Prostate Cancer Research
More informationProstate Cancer Screening. Dr. J. McCracken, Urologist
Prostate Cancer Screening Dr. J. McCracken, Urologist USPSTF Lifetime risk for diagnosis currently estimated at 15.9% Llifetime risk of dying of prostate cancer is 2.8% Seventy percent of deaths due to
More informationRole of MRI in the Diagnosis of Prostate Cancer, A Proposal
Clinical and Experimental Medical Sciences, Vol. 1, 2013, no. 3, 111 116 HIKARI Ltd, www.m-hikari.com Role of MRI in the Diagnosis of Prostate Cancer, A Proposal W. Akhter Research Fellow Urology, Bartshealth
More informationThe 4Kscore blood test for risk of aggressive prostate cancer
The 4Kscore blood test for risk of aggressive prostate cancer Early detection of aggressive prostate cancer Challenges Serum PSA has a high false positive rate Over 1 million prostate biopsies performed
More informationPSA Screening for Prostate Cancer Information for Care Providers
All men should know they are having a PSA test and be informed of the implications prior to testing. This booklet was created to help primary care providers offer men information about the risks and benefits
More informationProstate Cancer 2014
Prostate Cancer 2014 Eric A. Klein, M.D. Chairman Glickman Urological and Kidney Institute Professor of Surgery Cleveland Clinic Lerner College of Medicine Incidence rates, US Men Mortality Rates, US Men
More informationPSA screening: Controversies and Guidelines
PSA screening: Controversies and Guidelines John Phillips, MD, FACS Department of Urology Urology Center of Westchester New York Medical College Historical PerspecGve Cancer of the prostate, although rare,
More informationPROSTATE CANCER. Normal-risk men: No family history of prostate cancer No history of prior screening Not African-American
PROSTATE CANCER 1. Guidelines for Screening Risk Factors Normal-risk men: No family history of prostate cancer No history of prior screening Not African-American High-risk men: Family history of prostate
More informationProstate cancer is the most common cause of death from cancer in men over age 75. Prostate cancer is rarely found in men younger than 40.
A.D.A.M. Medical Encyclopedia. Prostate cancer Cancer - prostate; Biopsy - prostate; Prostate biopsy; Gleason score Last reviewed: October 2, 2013. Prostate cancer is cancer that starts in the prostate
More informationPSA screening in asymptomatic men the debate continues www.bpac.org.nz keyword: psa
PSA screening in asymptomatic men the debate continues www.bpac.org.nz keyword: psa Key messages: PSA is present in the benign and malignant prostate There is currently no national screening programme
More informationBeyond the PSA: Genomic Testing in Localized Prostate Cancer
Beyond the PSA: Genomic Testing in Localized Prostate Cancer Kelvin A. Moses, MD, PhD Vanderbilt University Medical Center Wednesday, December 2, 2015 5:00 p.m. ET/2:00 p.m. PT About ZERO ZERO s mission
More information1. What is the prostate-specific antigen (PSA) test?
1. What is the prostate-specific antigen (PSA) test? Prostate-specific antigen (PSA) is a protein produced by the cells of the prostate gland. The PSA test measures the level of PSA in the blood. The doctor
More informationDECISION AID TOOL PROSTATE CANCER SCREENING WITH PSA TESTING
DECISION AID TOOL PROSTATE CANCER SCREENING WITH PSA TESTING This booklet is what is often called a decision aid. The goals of a decision aid are to help people better understand their medical choices
More informationControversites: Screening for Prostate Cancer in Older Adults
Controversites: Screening for Prostate Cancer in Older Adults William Dale, MD, PhD University of Chicago Sections of Geriatrics & Palliative Medicine and Hematology/Oncology Director, Specialized Oncology
More informationProstate Cancer. Treatments as unique as you are
Prostate Cancer Treatments as unique as you are UCLA Prostate Cancer Program Prostate cancer is the second most common cancer among men. The UCLA Prostate Cancer Program brings together the elements essential
More informationThe PSA Controversy: Defining It, Discussing It, and Coping With It
The PSA Controversy: Defining It, Discussing It, and Coping With It 11 TH ANNUAL SYMPOSIUM ON MEN S HEALTH June 12, 2013 The PSA Controversy Defining It, Discussing It and Coping With It As of May 2012,
More informationOncology Annual Report: Prostate Cancer 2005 Update By: John Konefal, MD, Radiation Oncology
Oncology Annual Report: Prostate Cancer 25 Update By: John Konefal, MD, Radiation Oncology Prostate cancer is the most common cancer in men, with 232,9 new cases projected to be diagnosed in the U.S. in
More informationEarly Prostate Cancer: Questions and Answers. Key Points
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Early Prostate Cancer:
More informationScreening for Prostate Cancer
Screening for Prostate Cancer It is now clear that screening for Prostate Cancer discovers the disease at an earlier and more curable stage. It is not yet clear whether this translates into reduced mortality
More informationProstate Cancer Screening in Taiwan: a must
Prostate Cancer Screening in Taiwan: a must 吳 俊 德 基 隆 長 庚 醫 院 台 灣 醫 學 會 105 th What is the PSA test? The blood level of PSA is often elevated in men with prostate cancer, and the PSA test was originally
More informationThomas A. Kollmorgen, M.D. Oregon Urology Institute
Thomas A. Kollmorgen, M.D. Oregon Urology Institute None 240,000 new diagnosis per year, and an estimated 28,100 deaths (2012) 2 nd leading cause of death from cancer in U.S.A. Approximately 1 in 6 men
More informationA New Biomarker in Prostate Cancer Care: Oncotype Dx. David M Albala, MD Chief of Urology Crouse Hospital Syracuse, NY
A New Biomarker in Prostate Cancer Care: Oncotype Dx David M Albala, MD Chief of Urology Crouse Hospital Syracuse, NY Learning Objectives Review the current challenges in the prediction and prognosis of
More informationMEDICAL POLICY SUBJECT: PROSTATE CANCER SCREENING, DETECTION AND MONITORING
MEDICAL POLICY PAGE: 1 OF: 8 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationCancer in Primary Care: Prostate Cancer Screening. How and How often? Should we and in which patients?
Cancer in Primary Care: Prostate Cancer Screening How and How often? Should we and in which patients? PLCO trial (Prostate, Lung, Colorectal and Ovarian) Results In the screening group, rates of compliance
More informationProstate Cancer Screening: Are We There Yet? March 2010 Andrew M.D. Wolf, MD University of Virginia School of Medicine
Prostate Cancer Screening: Are We There Yet? March 2010 Andrew M.D. Wolf, MD University of Virginia School of Medicine Case #1 A 55 yo white man with well-controlled hypertension presents for his annual
More informationHistorical Basis for Concern
Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical
More informationProstate cancer screening. It s YOUR decision!
Prostate cancer screening It s YOUR decision! For many years now, a test has been available to screen for. The test is called the prostate-specific antigen blood test (or PSA test). It is used in combination
More informationAnalysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data
The 2014 Cancer Program Annual Public Reporting of Outcomes/Annual Site Analysis Statistical Data from 2013 More than 70 percent of all newly diagnosed cancer patients are treated in the more than 1,500
More informationDoes my patient need more therapy after prostate cancer surgery?
Does my patient need more therapy after prostate cancer surgery? Contact the GenomeDx Patient Care Team at: 1.888.792.1601 (toll-free) or e-mail: client.service@genomedx.com Prostate Cancer Classifier
More informationGuidelines for Cancer Prevention, Early detection & Screening. Prostate Cancer
Guidelines for Cancer Prevention, Early detection & Screening Prostate Cancer Intervention Comments & Recommendations For primary prevention, it has been suggested that diets low in meat & other fatty
More informationScreening for Cancer in Light of New Guidelines and Controversies. Christopher Celio, MD St. Jude Heritage Medical Group
Screening for Cancer in Light of New Guidelines and Controversies Christopher Celio, MD St. Jude Heritage Medical Group Screening Tests The 2 major objectives of a good screening program are: (1) detection
More informationPCa Commentary. Volume 73 January-February 2012 PSA AND TREATMENT DECISIONS:
1101 Madison Street Suite 1101 Seattle, WA 98104 P 206-215-2480 www.seattleprostate.com PCa Commentary Volume 73 January-February 2012 CONTENTS PSA SCREENING & BASIC SCIENCE PSA AND TREATMENT 1 DECISIONS
More informationOfficial reprint from UpToDate www.uptodate.com 2013 UpToDate
Official reprint from UpToDate www.uptodate.com 2013 UpToDate The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek
More informationThe Centers for Medicare & Medicaid Services (CMS) seeks stakeholder comments on the following clinical quality measure under development:
The Centers for Medicare & Medicaid Services (CMS) seeks stakeholder comments on the following clinical quality measure under development: Title: Non-Recommended PSA-Based Screening Description: The percentage
More informationNCCN Prostate Cancer Early Detection Guideline
NCCN Prostate Cancer Early Detection Guideline Joan McClure Senior Vice President National Comprehensive Cancer Network African American Prostate Cancer Disparity Summit September 22, 2006 Washington,
More informationThese rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma.
Prostate Cancer OVERVIEW Prostate cancer is the second most common cancer diagnosed among American men, accounting for nearly 200,000 new cancer cases in the United States each year. Greater than 65% of
More informationAdvice to patients about the PSA (prostate-specific antigen) blood test: frequently-asked questions
Advice to patients about the PSA (prostate-specific antigen) blood test: frequently-asked questions What is the PSA blood test? If you want more information before deciding to have this test, it is important
More informationUse of Androgen Deprivation Therapy (ADT) in Localized Prostate Cancer
Use of Androgen Deprivation Therapy (ADT) in Localized Prostate Cancer Adam R. Kuykendal, MD; Laura H. Hendrix, MS; Ramzi G. Salloum, PhD; Paul A. Godley, MD, PhD; Ronald C. Chen, MD, MPH No conflicts
More informationFAQ About Prostate Cancer Treatment and SpaceOAR System
FAQ About Prostate Cancer Treatment and SpaceOAR System P. 4 Prostate Cancer Background SpaceOAR Frequently Asked Questions (FAQ) 1. What is prostate cancer? The vast majority of prostate cancers develop
More informationPROSTATE CANCER. Get the facts, know your options. Samay Jain, MD, Assistant Professor,The University of Toledo Chief, Division of Urologic Oncology
PROSTATE CANCER Get the facts, know your options Samay Jain, MD, Assistant Professor,The University of Toledo Chief, Division of Urologic Oncology i What is the Prostate? Unfortunately, you have prostate
More informationBard: Prostate Cancer Treatment. Bard: Pelvic Organ Prolapse. Prostate Cancer. An overview of. Treatment. Prolapse. Information and Answers
Bard: Prostate Cancer Treatment Bard: Pelvic Organ Prolapse Prostate Cancer An overview of Pelvic Treatment Organ Prolapse Information and Answers A Brief Overview Prostate Anatomy The prostate gland,
More informationDescription of Procedure or Service. gene_based_tests_for_screening_detection_or_management_of_prostate_cancer 4/2009 8/2015 8/2016 8/2015
Corporate Medical Policy Gene-Based Tests for Screening, Detection, and/or Management File Name: Origination: Last CAP Review: Next CAP Review: Last Review: gene_based_tests_for_screening_detection_or_management_of_prostate_cancer
More information2010 SITE REPORT St. Joseph Hospital PROSTATE CANCER
2010 SITE REPORT St. Joseph Hospital PROSTATE CANCER Humboldt County is located on the Redwood Coast of Northern California. U.S census data for 2010 reports county population at 134,623, an increase of
More informationClinical Practice Guidelines
Clinical Practice Guidelines Prostate Cancer Screening CareMore Quality Management CareMore Health System adopts Clinical Practice Guidelines for the purpose of improving health care and reducing unnecessary
More informationScreening for Prostate Cancer
Screening for Prostate Cancer Review against programme appraisal criteria for the UK National Screening Committee (UK NSC) Version 1: This document summarises the work of ScHARR 1 2 and places it against
More informationUpdate on Prostate Cancer Screening Guidelines
www.medscape.com Update on Prostate Cancer Screening Guidelines Christine Gonzalez, PharmD, CHHC US Pharmacist Abstract and Introduction Introduction In the United States, prostate cancer is the most common
More informationBiomarkers for Prostate Cancer. Eric Wallen, MD Department of Urology
Biomarkers for Prostate Cancer Eric Wallen, MD Department of Urology Disclosure MDxHealth Scientific Advisor 55-year-old man: Poor Guy Risk of prostate cancer? 1 in 6 Risk of prostate cancer death? 1 in
More informationGleason Score. Oncotype DX GPS. identified for. about surveillance. time to get sophisticated
patient: MARK SMITH PSA 6.2 Gleason Score 6 Oncotype DX GPS 8 identified for active surveillance time to get sophisticated about surveillance Accurate prediction of prostate cancer risk is needed at the
More informationIndividual Prediction
Individual Prediction Michael W. Kattan, Ph.D. Professor of Medicine, Epidemiology and Biostatistics, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Chairman, Department
More informationNEW HYBRID IMAGING TECHNOLOGY MAY HAVE BIG POTENTIAL FOR IMPROVING DIAGNOSIS OF PROSTATE CANCER
Media Release April 7, 2009 For Immediate Release NEW HYBRID IMAGING TECHNOLOGY MAY HAVE BIG POTENTIAL FOR IMPROVING DIAGNOSIS OF PROSTATE CANCER London, Ontario Improved hybrid imaging techniques developed
More informationModeling Drivers of Cost and Benefit for Policy Development in Cancer
Modeling Drivers of Cost and Benefit for Policy Development in Cancer Harms? Benefits? Costs? Ruth Etzioni Fred Hutchinson Cancer Research Center Seattle, Washington The USPSTF recommends against routine
More informationProstate Cancer Early Detection: Update 2010
Prostate Cancer Early Detection: Update 2010 Prostate Cancer. Disease Burden The most common non-skin cancer, and the second leading cause of cancer death among U.S. men It is estimated that: 1 in 6 men
More informationReport with statistical data from 2007
2008 Cancer Program Annual Report with statistical data from 2007 Lake Cumberland Regional Hospital 305 Langdon Streett Somerset, KY 42503 Telephone: 606-679-7441 Fax: 606-678-9919 Cancer Committee Mullai,
More informationProstate cancer volume at biopsy vs. findings at Prostatectomy
Prostate cancer volume at biopsy vs. findings at Prostatectomy May 2005 By Shelly Smits, RHIT, CCS, CTR Ian Thompson, MD Data Source: Cancer registry data of prostate cancer treated with prostatectomy
More informationPSA Testing for Prostate Cancer An information sheet for men considering a PSA Test
PSA Testing for Prostate Cancer An information sheet for men considering a PSA Test What is the aim of this leaflet? Prostate cancer is a serious condition. The PSA test, which can give an early indication
More informationJurisdiction Virginia
PROPOSED/DRAFT Local Coverage Determination (LCD): MolDX: Prolaris Prostate Cancer Genomic Assay (DL35629) Please note: This is a Proposed/Draft policy. Proposed/Draft LCDs are works in progress that are
More informationKey Messages for Healthcare Providers
Cancer Care Ontario: Prostate Cancer Screening with the Prostate- Specific Antigen (PSA) Test Key Messages for Healthcare Providers Considerations for men at average risk Avoid prostate-specific antigen
More informationCMScript. Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014
Background CMScript Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014 Prostate cancer is second only to lung cancer as the leading cause of cancer-related deaths in men. It is
More informationMonitoring Clinical Stage to Improve Care
Monitoring Clinical Stage to Improve Care Stephen Dreyer, MD, FACS Cancer Liaison State Chair Nebraska Fremont, NE M. Asa Carter, CTR Manager, Accreditation and Standards American College of Surgeons Chicago,
More information7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
More informationProstate Cancer. Screening and Diagnosis. Screening. Pardeep Kumar Consultant Urological Surgeon
The Royal Marsden Prostate Cancer Screening and Diagnosis Pardeep Kumar Consultant Urological Surgeon Prostate Cancer Screening and Diagnosis 08 02 2013 2 Screening 1 3 Q1.Lots of men have prostate cancer
More informationProstate Cancer Screening Clinical Practice Guideline. Approved by the National Guideline Directors November, 2013
Prostate Cancer Screening Clinical Practice Guideline This guideline is informational only. It is not intended or designed as a substitute for the reasonable exercise of independent clinical judgment by
More informationH. RES. ll IN THE HOUSE OF REPRESENTATIVES RESOLUTION
112TH CONGRESS 1ST SESSION... (Original Signature of Member) H. RES. ll Recognizing the 40th anniversary of the National Cancer Act of 1971 and the more than 12,000,000 survivors of cancer alive today
More informationPROSTATE CANCER SCREENING PROSTATE CANCER SCREENING
3:45 4:45pm Screening Guidelines for Men's Health SPEAKER Radha Rao, MD Presenter Disclosure Information The following relationships exist related to this presentation: Radha Rao, MD: No financial relationships
More informationProstate-Specific Antigen Based Screening: Controversy and Guidelines
Prostate-Specific Antigen Based Screening: Controversy and Guidelines Eric H. Kim and Gerald L. Andriole Institutional Address: Washington University School of Medicine 4960 Children's Place Campus Box
More informationProstate Cancer Screening: Phantom menace to society. Folusho Ogunfiditimi, DM, MPH, PA-C Vattikuti Urology Institute Henry Ford Health System
Prostate Cancer Screening: Phantom menace to society Folusho Ogunfiditimi, DM, MPH, PA-C Vattikuti Urology Institute Henry Ford Health System Objectives USPTF Recommendations on PSA testing Justification
More informationReal Time MRI guided Focal Laser Ablation Therapy for Prostate Cancer
Real Time MRI guided Focal Laser Ablation Therapy for Prostate Cancer A/Prof Celi Varol and Dr Orit Raz Uro-Oncologist Nepean and Macquarie Hospital Trial at Macquarie University Hospital Ethics board
More informationNEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA)
NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA) Merat Esfahani, MD Medical Oncologist, Hematologist Cancer Liaison Physician SwedishAmerican Regional Cancer Center
More informationProstate Cancer Screening Guideline
Prostate Cancer Screening Guideline Contents Prevention 2 Screening Recommendations 2 Shared Decision Making 2 Test Recommendations 3 Follow-up/Referral 3 Treatment Overview 4 Evidence Summary 4 References
More informationUs TOO University Presents: Understanding Diagnostic Testing
Us TOO University Presents: Understanding Diagnostic Testing for Prostate Cancer Patients Today s speaker is Manish Bhandari, MD Program moderator is Pam Barrett, Us TOO International Made possible by
More informationWisconsin Cancer Data Bulletin Wisconsin Department of Health Services Division of Public Health Office of Health Informatics
Wisconsin Cancer Data Bulletin Wisconsin Department of Health Services Division of Public Health Office of Health Informatics In Situ Breast Cancer in Wisconsin INTRODUCTION This bulletin provides information
More informationCancer Screening. Robert L. Robinson, MD, MS. Ambulatory Conference SIU School of Medicine Department of Internal Medicine.
Cancer Screening Robert L. Robinson, MD, MS Ambulatory Conference SIU School of Medicine Department of Internal Medicine March 13, 2003 Why screen for cancer? Early diagnosis often has a favorable prognosis
More informationSecondary Cancer and Relapse Rates Following Radical Prostatectomy for Prostate-Confined Cancer
Copyright E 2007 Journal of Insurance Medicine J Insur Med 2007;39:242 250 MORTALITY Secondary Cancer and Relapse Rates Following Radical Prostatectomy for Prostate-Confined Cancer David Wesley, MD; Hugh
More informationCancer research in the Midland Region the prostate and bowel cancer projects
Cancer research in the Midland Region the prostate and bowel cancer projects Ross Lawrenson Waikato Clinical School University of Auckland MoH/HRC Cancer Research agenda Lung cancer Palliative care Prostate
More informationProstatectomy, pelvic lymphadenect. Med age 63 years Mean followup 53 months No other cancer related therapy before recurrence. Negative.
Adjuvante und Salvage Radiotherapie Ludwig Plasswilm Klinik für Radio-Onkologie, KSSG CANCER CONTROL WITH RADICAL PROSTATECTOMY ALONE IN 1,000 CONSECUTIVE PATIENTS 1983 1998 Clinical stage T1 and T2 Mean
More informationExamples of good screening tests include: mammography for breast cancer screening and Pap smears for cervical cancer screening.
CANCER SCREENING Dr. Tracy Sexton (updated July 2010) What is screening? Screening is the identification of asymptomatic disease or risk factors by history taking, physical examination, laboratory tests
More informationLocal Coverage Determination (LCD): MolDX: Genomic Health Oncotype DX Prostate Cancer Assay (L36153)
Local Coverage Determination (LCD): MolDX: Genomic Health Oncotype DX Prostate Cancer Assay (L36153) Contractor Information Contractor Name Palmetto GBA LCD Information Document Information LCD ID L36153
More informationOveruse of PSA Screening for Prostate Cancer in Older Men. Elizabeth Jaramillo, MD January 17, 2014
Overuse of PSA Screening for Prostate Cancer in Older Men Elizabeth Jaramillo, MD January 17, 2014 Screening Prostate cancer screening occurs in patients with no clinical sign or suspicion of disease Screening
More informationScience Highlights. To PSA or not to PSA: That is the Question.
Science Highlights June 2012 by Ann A. Kiessling, PhD at the To PSA or not to PSA: That is the Question. The current raucous debate over the commonly used PSA blood test to screen for prostate cancer,
More informationImplementation Date: April 2015 Clinical Operations
National Imaging Associates, Inc. Clinical guideline PROSTATE CANCER Original Date: March 2011 Page 1 of 5 Radiation Oncology Last Review Date: March 2015 Guideline Number: NIA_CG_124 Last Revised Date:
More informationThe Business of Prostate Cancer Care: A Clinician-Researcher s Perspective
The Business of Prostate Cancer Care: A Clinician-Researcher s Perspective David F. Penson, MD, MPH Departments of Urology and Preventive Medicine Keck School of Medicine University of Southern California
More informationFocus on PSA Screening for Prostate Cancer Vol. 28 Supplement, February 2012. Prostate Cancer: Should We Be Screening?
Focus on PSA Screening for Prostate Cancer Vol. 28 Supplement, February 2012 Prostate Cancer: Should We Be Screening? INSIDE THIS ISSUE 2 Why the Controversy? 3 Active Surveillance 4 The Radical Prostatectomy
More informationProstate Cancer Treatment
Scan for mobile link. Prostate Cancer Treatment Prostate cancer is a tumor of the prostate gland, which is located in front of the rectum and below the bladder. Your doctor may perform a physical exam,
More informationProstate Cancer Guide. A resource to help answer your questions about prostate cancer
Prostate Cancer Guide A resource to help answer your questions about prostate cancer Thank you for downloading this guide to prostate cancer treatment. We know that all the information provided online
More informationHEALTH NEWS PROSTATE CANCER THE PROSTATE
HEALTH NEWS PROSTATE CANCER THE PROSTATE Prostate comes from the Greek meaning to stand in front of ; this is very different than prostrate which means to lie down flat. The prostate is a walnut-sized
More informationAmerican Urological Association (AUA) Guideline
1 (AUA) Guideline EARLY DETECTION OF PROSTATE CANCER: AUA GUIDELINE Approved by the AUA Board of Directors April 2013 Authors disclosure of potential conflicts of interest and author/staff contributions
More informationTreating Prostate Cancer
Treating Prostate Cancer A Guide for Men With Localized Prostate Cancer Most men have time to learn about all the options for treating their prostate cancer. You have time to talk with your family and
More informationClinical Trials and Screening: What You Need to Know
Scan for mobile link. Clinical Trials and Screening: What You Need to Know What is a Clinical Trial? At A Glance A clinical trial is a research study that tests how well new medical techniques work in
More informationTreating Localized Prostate Cancer A Review of the Research for Adults
Treating Localized Prostate Cancer A Review of the Research for Adults Is this information right for me? Yes, this information is right for you if: Your doctor * said all tests show you have localized
More informationThe PSA Test for Prostate Cancer Screening:
For more information, please contact your local VA Medical Center or Health Clinic. U.S. Department of Veterans Affairs Veterans Health Administration Patient Care Services Health Promotion and Disease
More informationPSA Test Provides the Early Prostate Cancer Detection That Has Saved the Life of Thousands of Men
PSA Test Provides the Early Prostate Cancer Detection That Has Saved the Life of Thousands of Men Table of Contents 1. What the research shows on the effectiveness of the PSA test p. 2 2. PSA test guidelines
More information